Royalty Pharma Reports First Quarter 2024 Results
Royalty Pharma plc (Nasdaq: RPRX) reported 14% growth in Royalty Receipts driving Portfolio Receipts of $717 million for the first quarter of 2024. Full year 2024 guidance confirmed at $2,600 to $2,700 million with a commitment to grow dividends annually. The company's development-stage portfolio has expanded significantly, with key events expected in the coming year. Financial capacity of over $3.5 billion to execute transactions, despite a decline in Portfolio Receipts due to a high base of comparison. Strong Royalty Receipts growth and a focus on new royalty opportunities demonstrate a robust business strategy.
Royalty Receipts grew by 14%, driving Portfolio Receipts to $717 million for Q1 2024.
Confirmation of full year 2024 guidance at $2,600 to $2,700 million showcases stability and growth.
Expansion of the development-stage portfolio to 15 therapies with potential peak royalties significantly over $1 billion.
Portfolio Receipts declined from $1,131 million to $717 million due to a high base of comparison.
Milestones and other contractual receipts saw a significant decrease of 98% compared to the previous year.
Interest paid is expected to be approximately $160 million in 2024, impacting cash flow.
Insights
Upon analysis of Royalty Pharma's first quarter 2024 results, several financial indicators draw attention. While Royalty Receipts grew by 14%, this was overshadowed by the decrease in Portfolio Receipts by 37% and a similar reduction in Adjusted EBITDA and Portfolio Cash Flow, primarily due to a high base of comparison from a significant milestone payment in Q1 2023. This landscape suggests a one-time event significantly influenced the year-over-year comparison.
Their capital deployment strategy, including the acquisition of frexalimab's royalties, while costly, may enhance long-term value, considering the drug's potential market. The confidence in maintaining a mid-single digit percentage dividend growth also reflects a stable cash flow outlook. However, investors should consider the significant gap between current and previous year's net cash provided by operating activities, assessing whether this trend might affect future dividend sustainability.
From a medical research perspective, Royalty Pharma's investment in frexalimab—a Phase 3 therapy for multiple sclerosis—and the growth of their development-stage pipeline to 15 therapies underscore a strategic focus on high-potential drugs. Their portfolio's expansion, notably in rare diseases and oncology, aligns with industry trends prioritizing innovative and specialized treatments.
Investors should consider the inherent risk-reward nature of such investments, where successful outcomes may lead to substantial returns, but the path is fraught with regulatory hurdles and clinical uncertainties. Royalty Pharma's strategy to diversify within its portfolio across different therapeutic areas and development stages could mitigate some of this risk, offering a more balanced investment thesis within the biopharmaceutical royalty space.
From a market perspective, Royalty Pharma's commitment to expand its portfolio into high-growth areas such as cystic fibrosis and neuroscience aligns with the increasing market demand for new and effective treatments. The emerging healthcare trends showcase a significant market opportunity for innovative treatments, which Royalty Pharma seems poised to capitalize on. For retail investors, the key takeaway is the strategic positioning of the company in a diversified set of therapies with potential for high market adoption and royalty revenues.
Nonetheless, investors should balance expectations with the understanding that market dynamics in the pharmaceutical industry are complex, often influenced by regulatory environments, competitive products and the overall success rate of drug development.
- Royalty Receipts growth of
14% driving Portfolio Receipts of$717 million - Net cash provided by operating activities of
$665 million - Full year 2024 guidance confirmed: Portfolio Receipts expected to be
$2,600 t o$2,700 million - Commitment to grow dividend by mid-single digit percentage annually
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2024 and confirmed full year 2024 guidance for Portfolio Receipts.
“We continued to execute on our strategy in the first quarter of 2024 and are on track to deliver our full year guidance,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We achieved double-digit growth in Royalty Receipts driven by the strength of our diversified portfolio. With today’s transaction to acquire royalties on Sanofi’s frexalimab, a therapy with multi-blockbuster potential, we’ve increased our development-stage portfolio by five-fold to 15 medicines since our IPO. Looking ahead, 2024 is expected to be an event-rich year for our expanding development-stage pipeline with multiple potential regulatory and clinical events. Furthermore, we continue to be highly active in assessing attractive new royalty opportunities, reflecting the strong demand for capital to fund the ongoing wave of healthcare innovation. Based on the powerful fundamental tailwinds underpinning our business, we remain highly confident in our ability to deliver attractive, long-term compounding growth.”
Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison
- Royalty Receipts grew
14% to$705 million , driven by strong portfolio performance, including royalties on Evrysdi, Trelegy and the cystic fibrosis franchise. - Portfolio Receipts declined to
$717 million from$1,131 million , reflecting a$475 million Biohaven-related milestone payment received in the first quarter of 2023.
Capital Deployment of approximately
- Announced transaction to acquire royalties on Sanofi’s frexalimab, a potential multi-blockbuster in Phase 3 development for multiple sclerosis, for approximately
$525 million including estimated transaction costs. - Financial capacity of >
$3.5 billion (including cash and leverage capacity) to execute on value-creating transactions.
Development-stage portfolio growing to 15 therapies with potential significantly >
- 11 of 15 therapies are in Phase 3 development or undergoing regulatory review.
- Key events expected over next year: FDA filings for aficamten (cardiovascular), pelabresib (myelofibrosis); pivotal study results for seltorexant (depression), Tremfya (Crohn’s disease); FDA action date for KarXT (schizophrenia).
Financial guidance for full year 2024 (excludes contribution from future transactions)
- Royalty Pharma expects 2024 Portfolio Receipts to be between
$2,600 million and$2,700 million . - 2024 Portfolio Receipts guidance includes expected growth in Royalty Receipts of
5% to9% .
Financial & Liquidity Summary
| Three Months Ended March 31, | ||||
| (unaudited) | ||||
| ($ and shares in millions) | 2024 | 2023 | Change | |
| Portfolio Receipts | 717 | 1,131 | (37 | )% |
| Net cash provided by operating activities | 665 | 1,034 | (36 | )% |
| Adjusted EBITDA (non-GAAP)* | 656 | 1,044 | (37 | )% |
| Portfolio Cash Flow (non-GAAP)* | 584 | 977 | (40 | )% |
| Weighted average Class A ordinary shares outstanding - diluted | 597 | 607 | (2 | )% |
*See “Liquidity and Capital Resources” section. Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures calculated in accordance with the credit agreement.
Portfolio Receipts Highlights
| Three Months Ended March 31, | ||||||
| (unaudited) | ||||||
| ($ in millions) | 2024 | 2023 | Change | |||
| Products: | Marketers: | Therapeutic Area: | ||||
| Cystic fibrosis franchise | Vertex | Rare disease | 218 | 197 | 11 | % |
| Trelegy | GSK | Respiratory | 71 | 48 | 46 | % |
| Tysabri | Biogen | Neuroscience | 69 | 71 | (2 | )% |
| Imbruvica | AbbVie, J&J | Cancer | 50 | 57 | (12 | )% |
| Evrysdi | Roche | Rare disease | 45 | 18 | 156 | % |
| Promacta | Novartis | Hematology | 43 | 41 | 4 | % |
| Xtandi | Pfizer, Astellas | Cancer | 41 | 36 | 14 | % |
| Tremfya | Johnson & Johnson | Immunology | 36 | 32 | 15 | % |
| Cabometyx/Cometriq | Exelixis, Ipsen, Takeda | Cancer | 18 | 16 | 14 | % |
| Trodelvy | Gilead | Cancer | 10 | 7 | 57 | % |
| Erleada | Johnson & Johnson | Cancer | 9 | 6 | 57 | % |
| Orladeyo | BioCryst | Rare disease | 9 | 7 | 28 | % |
| Spinraza | Biogen | Rare disease | 7 | — | n/a | |
| Nurtec ODT/Zavzpret | Pfizer | Neuroscience | 6 | 4 | 40 | % |
| Other products(5) | 73 | 78 | (6 | )% | ||
| Royalty Receipts | 705 | 616 | 14 | % | ||
| Milestones and other contractual receipts | 12 | 515 | (98 | )% | ||
| Portfolio Receipts | 717 | 1,131 | (37 | )% | ||
Amounts shown in the table may not add due to rounding.
Portfolio Receipts were
Royalty Receipts increased
Liquidity and Capital Resources
Royalty Pharma’s liquidity and capital resources are summarized below:
As of March 31, 2024, Royalty Pharma had cash and cash equivalents of
| Liquidity Summary | Three Months Ended March 31, | |
| (unaudited) | ||
| ($ in millions) | 2024 | 2023 |
| Portfolio Receipts | 717 | 1,131 |
| Payments for operating and professional costs | (61) | (87) |
| Adjusted EBITDA (non-GAAP) | 656 | 1,044 |
| Interest paid, net | (73) | (67) |
| Portfolio Cash Flow (non-GAAP) | 584 | 977 |
- Adjusted EBITDA (non-GAAP) was
$656 million in the first quarter of 2024. Adjusted EBITDA is calculated in accordance with the credit agreement as Portfolio Receipts minus payments for operating and professional costs. - Portfolio Cash Flow (non-GAAP) was
$584 million in the first quarter of 2024. Portfolio Cash Flow is calculated in accordance with the credit agreement as Adjusted EBITDA minus interest paid or received, net. This measure reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases, or utilized for other discretionary investments.
Royalty Pharma has provided a reconciliation of each non-GAAP measure to the most directly comparable GAAP financial measure, net cash provided by operating activities, in Table 4.
Royalty Pharma announced new transactions of up to
The table below details Capital Deployment by category:
Capital Deployment
| Three Months Ended March 31, | ||
| ($ in millions) | 2024 | 2023 |
| Acquisitions of financial royalty assets | (86) | (602) |
| Development-stage funding payments - ongoing | (1) | (1) |
| Milestone payments | — | (12) |
| Investments in equity method investees | (7) | (4) |
| Contributions from legacy non-controlling interests - R&D | 0 | 0 |
| Capital Deployment | (93) | (618) |
Amounts may not add due to rounding.
Recent Transactions
During 2024, Royalty Pharma announced new transactions of up to
Recent transactions include:
- In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of
$49 million and up to$44 million in milestone payments contingent on the achievement of certain regulatory milestones. Ecopipam is in Phase 3 development by Emalex Biosciences for the treatment of Tourette Syndrome. - In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately
$525 million in cash including estimated transaction costs. ImmuNext is entitled to royalties on frexalimab, which is a first-in-class, second generation anti-CD40 ligand monoclonal antibody in development by Sanofi. Frexalimab is being evaluated in Phase 3 clinical studies for the treatment of multiple sclerosis and is in Phase 2 clinical studies for systemic lupus erythematosus and Type 1 Diabetes.
The information in this section should be read together with Royalty Pharma’s reports and documents filed with the SEC at www.sec.gov and the reader is also encouraged to review all other press releases and information available in the Investors section of Royalty Pharma’s website at www.royaltypharma.com.
Key Developments Relating to the Portfolio
The key developments related to Royalty Pharma’s royalty interests are discussed below based on disclosures from the marketers of the products.
| TEV-‘749 | In May 2024, Teva Pharmaceuticals announced positive efficacy results from its Phase 3 trial evaluating TEV-‘749, a once-monthly subcutaneous long-acting injection of olanzapine, in adult patients with schizophrenia. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the Positive and Negative Syndrome Scale (PANSS) total score from baseline after eight weeks compared to placebo. Additionally, no cases of Post-injection Delirium/Sedation Syndrome (PDSS) have been reported to date, after administration of approximately |
| Cystic fibrosis franchise | In May 2024, Vertex announced that it submitted a New Drug Application and Marketing Authorization Application for the new triple combination therapy to the Food & Drug Administration and the European Medicines Agency, respectively, for approval. This follows positive Phase 3 results for the new triple combination therapy in February 2024. In April 2024, Vertex announced that the European Commission had granted approval for the label expansion of Kalydeco for the treatment of infants down to one month of age with cystic fibrosis (CF) who have certain mutations in the CF transmembrane conductance regulator gene. |
| Tremfya | In May 2024, Johnson and Johnson announced positive Phase 3 results for Tremfya in patients with moderately to severely active Crohn’s disease with inadequate response/intolerance to conventional therapies and/or biologics. Johnson and Johnson submitted applications to the European Medicines Agency seeking to expand the Marketing Authorization Application for Tremfya to include ulcerative colitis and Crohn’s disease. |
| Xtandi | In April 2024, Astellas Pharma announced the European Commission approved a label extension for Xtandi as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy. In January 2024, Pfizer announced that the European Commission had approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi, for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated. |
| KarXT | In March 2024, Bristol Myers Squibb announced that it completed its acquisition of Karuna. Bristol Myers acquired Karuna for |
| Trontinemab | In March 2024, Roche held a neurology update event in which it announced that in people with Alzheimer’s Disease, trontinemab demonstrated rapid and robust amyloid plaque reduction at relatively low doses compared with standard anti-Aβ monoclonal antibodies. The sustained low Amyloid Related Imaging Abnormalities incidence and overall favorable safety and tolerability profile support further investigation. |
| Pelabresib | In February 2024, Novartis announced that it had entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys for |
| Trodelvy | In January 2024, Gilead announced that the Phase 3 EVOKE-01 study evaluating Trodelvy compared to docetaxel did not meet its primary endpoint of overall survival in patients with previously treated metastatic non-small cell lung cancer. |
2024 Financial Outlook
Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:
| Provided May 9, 2024 | Previous | |
| Portfolio Receipts | ||
| Payments for operating and professional costs | ||
| Interest paid |
The above Portfolio Receipts guidance includes expected Royalty Receipts growth of
Royalty Pharma’s full year 2024 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for 2024.
Total interest paid is based on the semi-annual interest payment schedule of Royalty Pharma’s existing notes and is anticipated to be approximately
Royalty Pharma today provides this guidance based on its most up-to-date view of its prospects. This guidance assumes no major unforeseen adverse events and excludes the contributions from transactions announced subsequent to the date of this press release. Furthermore, Royalty Pharma may amend its guidance in the event it engages in new royalty transactions which have a material near-term financial impact on the company.
Financial Results Call
Royalty Pharma will host a conference call and simultaneous webcast to discuss its first quarter 2024 results today at 8:00 a.m., Eastern Time. Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.
Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.
This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source.
For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission ("SEC") by visiting EDGAR on the SEC's website at www.sec.gov.
Portfolio Receipts
Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty receipts and Milestones and other contractual receipts. Royalty receipts includes variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”).
Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, neither of which are central to our fundamental business strategy.
Portfolio Receipts is calculated as the sum of the following line items from our GAAP statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests – Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships.
Use of Non-GAAP Measures
Adjusted EBITDA and Portfolio Cash Flow are non-GAAP liquidity measures that exclude the impact of certain items and therefore have not been calculated in accordance with GAAP. Management believes that Adjusted EBITDA and Portfolio Cash Flow are important non-GAAP measures used to analyze liquidity because they are key components of certain material covenants contained within Royalty Pharma’s credit agreement. Royalty Pharma cautions readers that amounts presented in accordance with the definitions of Adjusted EBITDA and Portfolio Cash Flow may not be the same as similar measures used by other companies or analysts. These non-GAAP liquidity measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for the analysis of Royalty Pharma’s results as reported under GAAP.
The definitions of Adjusted EBITDA and Portfolio Cash Flow used by Royalty Pharma are the same as the definitions in the credit agreement. Noncompliance with the interest coverage ratio, leverage ratio and Portfolio Cash Flow ratio covenants under the credit agreement could result in lenders requiring the company to immediately repay all amounts borrowed. If Royalty Pharma cannot satisfy these covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA and Portfolio Cash Flow are critical to the assessment of Royalty Pharma’s liquidity.
Adjusted EBITDA and Portfolio Cash Flow are used by management as key liquidity measures in the evaluation of the company’s ability to generate cash from operations. Management uses Adjusted EBITDA and Portfolio Cash Flow when considering available cash, including for decision-making purposes related to funding of acquisitions, debt repayments, dividends and other discretionary investments. Further, these non-GAAP liquidity measures help management, the audit committee and investors evaluate the company’s ability to generate liquidity from operating activities.
The company has provided reconciliations of these non-GAAP liquidity measures to the most directly comparable GAAP financial measure, being net cash provided by operating activities in Table 4.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
| Royalty Pharma plc Condensed Consolidated Statements of Operations (unaudited) Table 1 | ||
| Three Months Ended March 31, | ||
| ($ in millions) | 2024 | 2023 |
| Income and other revenues | ||
| Income from financial royalty assets | 542 | 665 |
| Other royalty income and revenues | 26 | 19 |
| Total income and other revenues | 568 | 684 |
| Operating expenses | ||
| Provision for changes in expected cash flows from financial royalty assets | 584 | 119 |
| Research and development funding expense | 1 | 1 |
| General and administrative expenses | 58 | 86 |
| Total operating expenses, net | 642 | 205 |
| Operating (loss)/income | (74) | 479 |
| Other expense/(income) | ||
| Equity in losses/(earnings) of equity method investees | 14 | (35) |
| Interest expense | 44 | 47 |
| Other income, net | (128) | (42) |
| Total other income, net | (70) | (30) |
| Consolidated net (loss)/income before tax | (4) | 509 |
| Income tax expense | — | — |
| Consolidated net (loss)/income | (4) | 509 |
| Net (loss)/income attributable to non-controlling interests | (9) | 168 |
| Net income attributable to Royalty Pharma plc | 5 | 341 |
Amounts may not add due to rounding.
| Royalty Pharma plc Selected Balance Sheet Data (unaudited) Table 2 | ||
| ($ in millions) | As of March 31, 2024 | As of December 31, 2023 |
| Cash and cash equivalents | 843 | 477 |
| Total current and non-current financial royalty assets, net | 14,126 | 14,827 |
| Total assets | 16,131 | 16,382 |
| Long-term debt | 6,139 | 6,135 |
| Total liabilities | 6,267 | 6,298 |
| Total shareholders’ equity | 9,864 | 10,084 |
| Royalty Pharma plc Condensed Consolidated Statements of Cash Flows (unaudited) Table 3 | ||
| Three Months Ended March 31, | ||
| ($ in millions) | 2024 | 2023 |
| Cash flows from operating activities: | ||
| Cash collections from financial royalty assets | 745 | 1,152 |
| Cash collections from intangible royalty assets | 14 | 1 |
| Other royalty cash collections | 26 | 20 |
| Distributions from equity method investees | 13 | 16 |
| Interest received | 6 | 16 |
| Development-stage funding payments – ongoing | (1) | (1) |
| Payments for operating and professional costs | (61) | (87) |
| Interest paid | (79) | (83) |
| Net cash provided by operating activities | 665 | 1,034 |
| Cash flows from investing activities: | ||
| Distributions from equity method investees | 5 | 35 |
| Investments in equity method investees | (7) | (4) |
| Proceeds from available for sale debt securities | 1 | — |
| Proceeds from sales and maturities of marketable securities | — | 24 |
| Acquisitions of financial royalty assets | (86) | (602) |
| Milestone payments | — | (12) |
| Net cash used in investing activities | (87) | (559) |
| Cash flows from financing activities: | ||
| Distributions to legacy non-controlling interests – Portfolio Receipts | (88) | (92) |
| Distributions to continuing non-controlling interests | (32) | (33) |
| Dividends to shareholders | (94) | (89) |
| Contributions from legacy non-controlling interests – R&D | 0 | 0 |
| Contributions from non-controlling interests – other | 1 | 3 |
| Net cash used in financing activities | (212) | (210) |
| Net change in cash and cash equivalents | 366 | 265 |
| Cash and cash equivalents, beginning of period | 477 | 1,711 |
| Cash and cash equivalents, end of period | 843 | 1,976 |
Amounts may not add due to rounding.
| Royalty Pharma plc GAAP to Non-GAAP Reconciliation (unaudited) Table 4 | ||
| Three Months Ended March 31, | ||
| ($ in millions) | 2024 | 2023 |
| Net cash provided by operating activities (GAAP) | 665 | 1,034 |
| Adjustments: | ||
| Proceeds from available for sale debt securities(6) | 1 | — |
| Distributions from equity method investees(6) | 5 | 35 |
| Interest paid, net(6) | 73 | 67 |
| Development-stage funding payments – ongoing | 1 | 1 |
| Distributions to legacy non-controlling interests – Portfolio Receipts(6) | (88) | (92) |
| Adjusted EBITDA (non-GAAP) | 656 | 1,044 |
| Interest paid, net(6) | (73) | (67) |
| Portfolio Cash Flow (non-GAAP) | 584 | 977 |
Amounts may not add due to rounding.
| Royalty Pharma plc Description of Approved Indications for Select Portfolio Therapies Table 5 |
| Cystic fibrosis franchise | Cystic fibrosis |
| Trelegy | Chronic obstructive pulmonary disease and asthma |
| Tysabri | Relapsing forms of multiple sclerosis |
| Imbruvica | Hematological malignancies and chronic graft versus host disease |
| Evrysdi | Spinal muscular atrophy |
| Promacta | Chronic immune thrombocytopenia purpura and aplastic anemia |
| Xtandi | Prostate cancer |
| Tremfya | Plaque psoriasis and active psoriatic arthritis |
| Cabometyx/Cometriq | Kidney, liver and thyroid cancer |
| Trodelvy | Breast and bladder cancer |
| Erleada | Prostate cancer |
| Orladeyo | Hereditary angioedema |
| Spinraza | Spinal muscular atrophy |
| Nurtec ODT | Acute and preventative treatment of migraine |
Notes
| (1) | Portfolio Receipts is a key performance metric that represents our ability to generate cash from our portfolio investments, the primary source of capital that we can deploy to make new portfolio investments. Portfolio Receipts is defined as the sum of Royalty receipts and milestones and other contractual receipts. Royalty receipts include variable payments based on sales of products, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma (“Royalty Receipts”). Milestones and other contractual receipts include sales-based or regulatory milestone payments and other fixed contractual receipts, net of contractual payments to the legacy non-controlling interests, that are attributed to Royalty Pharma. Portfolio Receipts does not include proceeds from equity securities or marketable securities, both of which are not central to our fundamental business strategy. Portfolio Receipts is calculated as the sum of the following line items from our GAAP statements of cash flows: Cash collections from financial royalty assets, Cash collections from intangible royalty assets, Other royalty cash collections, Proceeds from available for sale debt securities and Distributions from equity method investees less Distributions to legacy non-controlling interests - Portfolio Receipts, which represent contractual distributions of Royalty Receipts, milestones and other contractual receipts to RPSFT and the Legacy Investors Partnerships. |
| (2) | Adjusted EBITDA is defined under the credit agreement as Portfolio Receipts minus payments for operating and professional costs. Operating and professional costs reflect Payments for operating and professional costs from the GAAP statements of cash flows. See GAAP to Non-GAAP reconciliation in Table 4. |
| (3) | Portfolio Cash Flow is defined under the credit agreement as Adjusted EBITDA minus interest paid or received, net. See GAAP to Non-GAAP reconciliation in Table 4. Portfolio Cash Flow reflects the cash generated by Royalty Pharma’s business that can be redeployed into value-enhancing royalty acquisitions, used to repay debt, returned to shareholders through dividends or share purchases or utilized for other discretionary investments. |
| (4) | Capital Deployment is calculated as the summation of the following line items from our GAAP statements of cash flows: Investments in equity method investees, Purchases of available for sale debt securities, Acquisitions of financial royalty assets, Acquisitions of other financial assets, Milestone payments, Development-stage funding payments - ongoing, Development-stage funding payments - upfront and milestone less Contributions from legacy non-controlling interests - R&D. |
| (5) | Other products primarily include Royalty Receipts on the following products: Cimzia, Crysvita, Emgality, Entyvio, Farxiga/Onglyza, IDHIFA, Letairis, Lexiscan, Mircera, Nesina, Soliqua and distributions from the Legacy SLP Interest, which is presented as Distributions from equity method investees on the GAAP statements of cash flows. |
| (6) | The table below shows the line item for each adjustment and the direct location for such line item on the GAAP statements of cash flows. |
| Reconciling Adjustment | Statements of Cash Flows Classification |
| Interest paid, net | Operating activities (Interest paid less Interest received) |
| Distributions from equity method investees | Investing activities |
| Proceeds from available for sale debt securities | Investing activities |
| Distributions to legacy non-controlling interests - Portfolio Receipts | Financing activities |
FAQ
<p>What was the growth rate of Royalty Receipts for Royalty Pharma in Q1 2024?</p>
Royalty Receipts grew by 14% to $705 million.
<p>What is Royalty Pharma's guidance for full year 2024 Portfolio Receipts?</p>
Royalty Pharma expects Portfolio Receipts to be between $2,600 million and $2,700 million for 2024.
<p>How many therapies are included in Royalty Pharma's development-stage portfolio?</p>
Royalty Pharma's development-stage portfolio consists of 15 therapies with potential significantly over $1 billion in peak royalties.
